The most sensitive blood test for Alzheimer’s risk.
Discover what is happening in your brain, even before symptoms appear. Now in Australia
Inside the brain risk insights panel
You can now detect through indicators early brain changes linked to Alzheimer’s disease - before noticeable symptoms appear.
BrainScan by neurocode advanced p-tau 217 test offers unmatched accuracy for detecting Alzheimer’s amyloid pathology.
For adults aged 35 and over, the p-Tau 217, GFAP, and NfL blood tests offer early detection of cognitive decline - providing a proactive foundation for prevention strategies through personalized or group based lifestyle interventions. The brain risk insights panel measures:
High-sensitivity p-tau 217: Detects early signs of Alzheimer’s disease by measuring subtle changes in tau 217 proteins - closely aligned with amyloid pathology and among the most predictive markers available.
GFAP (Glial Fibrillary Acidic Protein): Indicates levels of brain inflammation and injury, offering a clearer picture of how healthy and resilient your brain’s support cells are.
NfL (Neurofilament Light Chain): Measures nerve cell damage to help monitor ongoing brain health and track changes that may need attention.
The test is available to order directly through our collaborative partners at Optilabs.
You’ve received your BrainScan report. Now what?
We support you in learning about your report and taking the next steps, guiding your journey to discover the possible contributing factors and take personalised functional and lifestyle intervention actions. You are invited to schedule your BrainScan report session here: